Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations
10.3969/j.issn.1001-5256.2016.12.021
- VernacularTitle:肝动脉化疗栓塞术后行经皮射频消融术治疗高危部位原发性肝癌的效果和安全性分析
- Author:
Wei SUN
1
;
Xiaoyan DING
;
Jinglong CHEN
Author Information
1. Department of Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
- Publication Type:Research Article
- Keywords:
liver neoplasms;
chemoembolization, therapeutic;
catheter ablation;
postoperative complications;
treatment outcome
- From:
Journal of Clinical Hepatology
2016;32(12):2337-2341
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the clinical effect and safety of percutaneous radiofrequency ablation (RFA) following transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer in high-risk locations. MethodsThe patients with primary liver cancer in high-risk locations who were diagnosed and treated from January 2011 to December 2015 were enrolled. All the patients underwent TACE followed by CT-guided RFA 3-5 days later. The treatment outcome and adverse events were observed. ResultsA total of 64 patients with 76 lesions were enrolled and all of them completed TACE and RFA. At one month after surgery, the complete tumor ablation rate was 81.5% (62/76). The patients were followed up for 6 to 64 months after surgery; at the end of follow-up, the local tumor progression rate was 28.9% (22/76), and the 1-, 2-, and 3-year survival rates were 90.6%, 78.1%, and 64.1%, respectively. The incidence rate of severe surgical complications during follow-up was 3.1% (one patient each experienced liver abscess and hematobilia), and the patients achieved remission after medical treatment and interventional treatment without any sequel. ConclusionCT-guided RFA after TACE is a safe and feasible regimen for primary liver cancer in high-risk locations.
